Effect of aspirin on disability-free survival in the healthy elderly

New England Journal of Medicine

Volumn 379, Issue 16, 2018, Pages 1499-1508

  McNeil, J J ^a   Woods, R L ^a   Nelson, M R ^a,e   Reid, C M ^a,f   Kirpach, B ^j   Wolfe, R ^a   Storey, E ^a   Shah, R C ^l   Lockery, J E ^a   Tonkin, A M ^a   Newman, A B ^m   Williamson, J D ^m   Margolis, K L ^j   Ernst, M E ⁿ   Abhayaratna, W P ^h   Stocks, N ⁱ   Fitzgerald, S M ^a   Orchard, S G ^a   Trevaks, R E ^a   Beilin, L J ^g   Donnan, G A ^d   Gibbs, P ^b   Johnston, C I ^a,c   Ryan, J ^a   Radziszewska, B ^o   Grimm, R ^j   Murray, A M ^j,k   more..

^a MONASH UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF TASMANIA   (Australia)

^f CURTIN UNIVERSITY   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

ⁱ UNIVERSITY OF ADELAIDE   (Australia)

^j UNIVERSITY OF MINNESOTA   (United States)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF IOWA   (United States)

^o NATIONAL INSTITUTE ON AGING   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; ASIAN; AUSTRALIA; BLACK PERSON; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMMUNITY DWELLING PERSON; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMENTIA; DISABILITY FREE SURVIVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ENTERIC COATED TABLET; FEMALE; FOLLOW UP; HAZARD RATIO; HISPANIC; HUMAN; MALE; MORTALITY; PATIENT COMPLIANCE; PHYSICAL DISABILITY; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE; UNITED STATES; CHEMICALLY INDUCED; CLINICAL TRIAL; DISABLED PERSON; DOUBLE BLIND PROCEDURE; INCIDENCE; INDEPENDENT LIVING; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ASPIRIN; AUSTRALIA; DEMENTIA; DISABLED PERSONS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; INDEPENDENT LIVING; MALE; MORTALITY; PLATELET AGGREGATION INHIBITORS; TREATMENT FAILURE; UNITED STATES;

EID: 85053515177     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1800722     Document Type: Article

References (34)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
3. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388: 365-75.
4. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-12.
5. Rothwell PM. Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits. Recent Results Cancer Res 2013; 191: 121-42.
6. Sutcliffe P, Connock M, Gurung T, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol Assess 2013; 17: 1-253.
7. Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Aspirin use in adults: cancer, all-cause mortality, and harms: a systematic evidence review for the U.S. Preventive Services Task Force. Evidence syntheses no. 132. Rockville, MD: Agency for Healthcare Research and Quality, 2015 (https://www.ncbi.nlm.nih.gov/books/NBK321643/).
8. Chubak J, Whitlock EP, Williams SB, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med 2016; 164: 814-25.
9. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2016; 164: 826-35.
10. Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on longterm antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017; 390: 490-9.
11. ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 2013; 36: 555-64.
12. Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008; 189: 105-9.
13. McNeil JJ, Woods RL, Nelson MR, et al. Baseline characteristics of participants in the ASPREE (ASPirin in Reducing Events in the Elderly) study. J Gerontol A Biol Sci Med Sci 2017; 72: 1586-93.
14. Chin AL, Negash S, Hamilton R. Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord 2011; 25: 187-95.
15. Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation 2017; 136(21): e393-e423.
16. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987; 48: 314-8.
17. Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 1983; 31: 721-7.
18. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM IV. Washington, DC: American Psychiatric Association, 1994.
19. McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018; 379: 1509-18.
20. McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018; 379: 1519-28.
21. Wolfe R, Murray AM, Woods RL, et al. The aspirin in reducing events in the elderly trial: statistical analysis plan. Int J Stroke 2018; 13: 335-8.
22. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313-6.
23. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
24. Kassoff A, Buzney SM, McMeel JW, et al. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 1. JAMA 1992; 268: 1292-300.
25. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
26. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62
27. de Gaetano G, Collaborative Group of the Primary Prevention Project. Lowdose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
28. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
29. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
30. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-41.
31. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-8.
32. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312: 2510-20.
33. Gauthier SG. Alzheimer's disease: the benefits of early treatment. Eur J Neurol 2005; 12: Suppl 3: 11-6.
34. Winblad B, Wimo A, Engedal K, et al. 3-Year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353-63.